GLP-1 Science
GLP-1 and Smoking Cessation Research
Emerging research suggests semaglutide may reduce tobacco use, an unexpected finding still being actively studied. Here...
Retatrutide produced the largest weight loss ever recorded in an obesity drug trial. In its phase 2 study, the highest dose reduced body weight by an average of 24.2 percent over 48 weeks.
That figure is genuinely remarkable. It approaches what bariatric surgery achieves. It is also a phase 2 result for a drug that is not approved anywhere in the world, and both halves of that sentence matter.
What retatrutide is
Retatrutide is an investigational once-weekly injection developed by Eli Lilly. It is described as a triple-hormone-receptor agonist, meaning it activates three separate receptors at once.
Every drug before it targeted fewer. Semaglutide targets one. Tirzepatide targets two. Retatrutide targets three.
The three receptors
GLP-1 (glucagon-like peptide-1) is the gut hormone released after eating that slows stomach emptying, signals fullness to your brain and prompts insulin release. This is the pathway every drug in this family uses.
GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone released after eating. It stimulates insulin and appears to influence how fat tissue stores and processes energy. Adding GIP is what made tirzepatide stronger than semaglutide.
Glucagon is the interesting addition, and it seems counterintuitive at first. Glucagon raises blood sugar, which sounds like the opposite of what you want. But it also increases energy expenditure, meaning your body burns more calories at rest, and it promotes breakdown of fat stored in the liver.
The first two receptors reduce how much you eat. The third increases how much you burn. That combination is why retatrutide's results exceed anything before it.
Balancing glucagon action against its blood-sugar-raising effect is the delicate part of the drug's design, and it is one reason this approach took so long to become viable.
What the trial found
The phase 2 trial was published in the New England Journal of Medicine in 2023. It enrolled 338 adults with a BMI of 30 or above, or 27 to 30 with at least one weight-related condition, randomly assigned to retatrutide at 1 mg, 4 mg, 8 mg or 12 mg weekly, or placebo, for 48 weeks.
At 24 weeks, average weight reductions were 7.2 percent at 1 mg, 12.9 percent in the combined 4 mg group and 17.3 percent in the combined 8 mg group.
At 48 weeks, the 8 mg dose produced 22.8 percent and the 12 mg dose produced 24.2 percent.
For context against the approved drugs:
| Drug | Weight loss | Trial |
|---|---|---|
| Retatrutide 12 mg | 24.2 percent | Phase 2, 48 weeks |
| Tirzepatide 15 mg | 20.9 percent | SURMOUNT-1, 72 weeks |
| Semaglutide 2.4 mg | 14.9 percent | STEP 1, 68 weeks |
Retatrutide achieved more in 48 weeks than tirzepatide achieved in 72. The weight curve had also not flattened by the end of the trial, which suggests longer treatment might produce more.
Why phase 2 is not the finish line
This is where enthusiasm needs tempering, and it is the part most coverage of retatrutide skips.
Phase 2 trials are relatively small and relatively short. This one had 338 participants over 48 weeks. Phase 3 trials enrol thousands and run longer, and they exist precisely because phase 2 results do not always hold.
Drugs fail at phase 3 regularly. Effects shrink in larger and more diverse populations. Safety signals that were invisible in 338 people become visible in 5,000.
Glucagon receptor activation deserves particular scrutiny. Increasing energy expenditure is the mechanism behind retatrutide's advantage, but it also raises heart rate, and its effect on blood sugar in a wider population needs careful assessment. Phase 3 is where those questions get answered.
The honest position is that retatrutide looks extraordinarily promising and is not yet proven.
Side effects reported so far
The pattern was consistent with the drug class. Nausea, diarrhoea, vomiting and constipation were the most common, and were dose-related, meaning higher doses produced more.
Increased heart rate was observed, which is expected given glucagon receptor activation.
Longer-term and rarer effects are simply not known yet. That is what phase 3 determines.
The counterfeit warning
This section is the most practically important thing in this article.
Retatrutide is not approved in any country. It cannot be legally prescribed or sold as a medicine anywhere.
Despite that, it is sold online. It appears on research chemical websites, through peptide sellers, and on social media, frequently marketed to people who have read about the 24 percent figure.
Anything sold as retatrutide today is unregulated. Nobody has verified its identity, purity, concentration or sterility. There is no manufacturing oversight, no pharmacovigilance, and no recourse if it harms you.
Some of these products contain nothing. Some contain something else entirely. Some are contaminated. Injecting an unverified substance sourced from an unregulated seller is a serious risk, and the appeal of the headline number is exactly what makes people take that risk.
If you take one thing from this article, take this: a drug that is not approved is not available, and anything presenting itself otherwise is not what it claims to be.
What this means for Pakistan
Retatrutide is years away from being available here, if it is ever registered at all. Pakistan is not typically an early launch market for new obesity drugs, and even approved GLP-1 medications like semaglutide and tirzepatide have never achieved registration here.
The realistic picture is that by the time retatrutide is obtainable in Pakistan through legitimate channels, the current generation will have been available for many years.
That gap between what exists in trials and what Pakistani patients can access today is the practical reality worth planning around. METASLIM™ is a physician-reviewed GLP-1 sublingual supplement, not a pharmaceutical agonist of any kind, so retatrutide's trial figures have no bearing on it whatsoever and nobody should imply otherwise. What it offers is something obtainable now, with a physician reviewing each order before dispatch.
That physician review is the point of difference against buying an unverified peptide online. Our page on why physician oversight matters covers what that involves. The complete GLP-1 medication list covers approved options, and what Zepbound is covers the strongest one currently available.
The summary
Retatrutide's 24.2 percent phase 2 result is the most impressive figure this field has produced, and its triple-receptor mechanism is a genuine advance rather than an incremental tweak.
It is also unapproved, unproven at phase 3, and unavailable through any legitimate route.
Both things are true simultaneously. Being excited about where this field is heading is reasonable. Injecting an unregulated substance because of a headline number is not.
Check availability and cash-on-delivery options for something you can actually obtain safely today.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.